Table II.
Major Clinical Trials Showing Benefit of Treating Isolated Systolic Hypertension
| SHEP (n=4736) | Syst‐Eur (n=4695) | Syst ‐China (n=2394) | |
|---|---|---|---|
| Baseline BP | 160‐219/<90 | 160‐219/<95 | 160‐219/<95 |
| SBP/DBP (mm Hg) | |||
| BP reduction: | 27/9 | 23/7 | 20/5 |
| SBP/DPB (mm Hg) | |||
| Drug therapy | Chlorthalidone Atenolol | Nitrendipine Enalapril HCTZ | Nitrendipine Captopril HCTZ |
| Outcomes (%↓) | |||
| Stroke | 33 | 42 | 38 |
| CAD | 27 | 30 | 27 |
| CHF | 55 | 29 | ‐ |
| All CVD | 32 | 31 | 25 |
| BP=blood pressure; SBP/DBP=systolic/diastolic BP; CAD=coronary artery disease; CHF=congestive heart failure; CVD=cardiovascular disease; HCTZ=hydrochlorothiazide; SHEP=Systolic Hypertension in the Elderly Program; Syst‐Eur=Systolic Hypertension‐Europe trial; Syst‐China=Systolic Hypertension‐China trial | |||